International Trial Introduces Another Curative Option for Sickle Cell Disease
June 26, 2024
June 26, 2024
NASHVILLE, Tennessee, June 26 (TNSres) -- Vanderbilt University Medical Center issued the following news release:
* * *
The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.
* * *
Vanderbilt University Medical Center (VUMC) researchers are touting data from a multicenter, internati . . .
* * *
The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.
* * *
Vanderbilt University Medical Center (VUMC) researchers are touting data from a multicenter, internati . . .